Ablynx

Activities

Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonology.

Products and services

Today, the Company has more than 30 programmes in the pipeline and six Nanobodies are at the clinical development stage.

Projects

 

Area of interest

International projects

The power of the Nanobody platform is such that Ablynx has the opportunity to generate development candidates across a range of therapeutic areas in just over two years. The breadth of the Nanobody platform and the efficiency with which leads are generated, has created partnering opportunities ranging from early-stage leads to clinical-stage licensing opportunities. Ablynx continues to advance its own Nanobody research and development programmes with the goal of building a unique proprietary pipeline. Ablynx will selectively choose to partner with companies that have therapeutic expertise in relevant disease areas and a significant commitment to development and commercialisation of biologics. Ablynx has an interest in exploring partnerships where alternative routes of administration could offer an advantage over existing therapies. Ablynx is currently looking for partners to develop and commercialise the following assets outside of Greater China: anti-TNFα Nanobody, ozoralizumab, which achieved clinical proof-of-concept in a Phase II study in RA patients; and anti-RANKL Nanobody, ALX-0141, which successfully completed a Phase I clinical trial. The Company is happy to discuss the licensing of other on-going clinical development programmes. More information To learn more about drug discovery collaborations and licensing opportunities with Ablynx, please contact Holger Neecke, Senior Director Business Development or Cedric Ververken, Director Business Development.